APA (7th ed.) Citation

Waterer, G., Lord, J., Hofmann, T., & Jouhikainen, T. (2020). Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: A New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy, 64(3), . https://doi.org/10.1128/AAC.01776-19

Chicago Style (17th ed.) Citation

Waterer, Grant, John Lord, Thomas Hofmann, and Taneli Jouhikainen. "Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: A New Approach to Therapy for Methicillin-Resistant Staphylococcus Aureus." Antimicrobial Agents and Chemotherapy 64, no. 3 (2020). https://doi.org/10.1128/AAC.01776-19.

MLA (9th ed.) Citation

Waterer, Grant, et al. "Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: A New Approach to Therapy for Methicillin-Resistant Staphylococcus Aureus." Antimicrobial Agents and Chemotherapy, vol. 64, no. 3, 2020, https://doi.org/10.1128/AAC.01776-19.